Palliative Care for Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acute Myeloid LeukemiaPalliative Care - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a palliative care team working with an oncology team will improve end-of-life outcomes and quality of life for AML patients receiving non-intensive therapy.

Eligible Conditions
  • Acute Myeloid Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
UCART19 follow-up
1
Minnelide
1
TAS1440

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: 2 years

2 years
Compare quality of end-of-life care between the two study arms
Patient-report of discussing end-of-life care preferences based on an item from the perception of treatment and prognosis questionnaire
Rate of hospice utilization and length-of-stay in hospice
Rates of death in the hospital
Rates of documentation of end-of-life care preferences at least one week prior to death.
Time from documentation of end-of-life care preferences to death
one month
caregiver-reported discussion of end-of-life care preferences as measured by the perception of treatment and prognosis questionnaire
up to 2 years
compare changes in mood
compare changes in symptom burden
up to 30 days
Compare Rate of hospitalization between the study arms
Day 30
Rate of chemotherapy administration
up to one year
compare changes in quality of life

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
UCART19 follow-up
1
Minnelide
1
TAS1440

Trial Design

2 Treatment Groups

Standard leukemia care
1 of 2
Collaborative palliative and oncology care
1 of 2

Active Control

Experimental Treatment

320 Total Participants · 2 Treatment Groups

Primary Treatment: Palliative Care · No Placebo Group · N/A

Collaborative palliative and oncology careExperimental Group · 2 Interventions: Standard Leukemia care, Palliative Care · Intervention Types: Other, Other
Standard leukemia care
Other
ActiveComparator Group · 1 Intervention: Standard Leukemia care · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,699 Previous Clinical Trials
30,842,812 Total Patients Enrolled
Areej El-Jawahri, MDPrincipal InvestigatorMassachusetts General Hospital
16 Previous Clinical Trials
4,295 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to comprehend English or complete questionnaires with minimal assistance of an interpreter.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top